Financial Times: Analysts at Jefferies said the semaglutide patent expiry in India had seen the launch of “brands galore” by about 10 drugmakers so far as they chase a “magic pill moment” and a local market worth potentially $500mn-$1bn.
Analysts at Nomura estimated Indian drugmakers could charge Rs3,500-Rs8,000 ($37-$85) a month for disposable pen injections, far lower than the Rs11,000-Rs16,000 for western branded versions…